Myriad Genetics (MYGN)

• Market cap: $1.29B
• 1 day: -5.34%
• 5 days: -4.38%
• 1 month: 12.81%
• 3 months: -6.22%
• 6 months: -49.23%
• Year to date: 5.04%
• 1 year: -38.11%
• 5 years: -27.84%
• 10 years: -59.57%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Employees: 2,700

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,343% more call options, than puts

Call options by funds: $4.1M | Put options by funds: $284K

22% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 73

0.95% more ownership

Funds ownership: 100.52% [Q3] → 101.47% (+0.95%) [Q4]

12% less funds holding

Funds holding: 246 [Q3] → 216 (-30) [Q4]

45% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 55

49% less capital invested

Capital invested by funds: $2.5B [Q3] → $1.27B (-$1.23B) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13 8% downside
• Avg. target: $19 34% upside
• High target: $29 105% upside

7 analyst ratings

• positive: 2 29%
• neutral: 4 57%
• negative: 1 14%

Craig-Hallum John Wilkin 100% 1-year accuracy 1 / 1 met price target	105% upside $29	Buy Initiated	12 Feb 2025
Piper Sandler John Peterson 0 / 0 met price target	1% downside $14	Neutral Maintained	30 Jan 2025
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	27% upside $18	Buy Maintained	28 Jan 2025
Stephens & Co. Mason Carrico 40% 1-year accuracy 8 / 20 met price target	41% upside $20	Equal-Weight Reiterated	16 Jan 2025
B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	8% downside $13	Underperform Maintained	13 Dec 2024